MainTotal number of new labels (postmarketing) approved in the fiscal year that include clinical pharmacology review on pharmacogenetic, drug-drug interactions and specific population information, etc.These labeling update are considered important to enhance the safe and effective use of drug products even after they are approved. Most times they are based on new knowledge and fulfillment of post-marketing requirement or commitment.<br>These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research. </b>Number2011Measure was implemented starting January 20112012FY 2012 YTD: 62MainCumulative number of new labels (postmarketing) approvedThese labeling update are considered important to enhance the safe and effective use of drug products even after they are approved. Most times they are based on new knowledge and fulfillment of post-marketing requirement or commitment.Numbercolumn2011Measure was implemented starting January 20112012FY 2012 YTD: 206http://www.fda.gov/AboutFDA/Transparency/track/ucm206444.htmFDA-TRACK CDER Dashboard